Latest Strategic Growth Initiatives News

DomaCom Limited reports a transformative quarter with executive changes, new funding facilities, and strategic initiatives including the launch of its Homeowner Equity Fund and exclusive licensing of the Bricklet Homeowner Platform.

HeraMED reports a surge in its HeraCARE platform users and secures $4.1 million in new funding, underpinning its expansion in the US maternity care market and integration with major health systems.

IODM Limited reported a decline in cash reserves to $461,000 for the December quarter, while projecting revenue growth through new university client onboarding in the UK and North America.

Credit Clear Limited has reported a robust first half of FY25 with record revenue and a significant rise in profitability, reaffirming its full-year guidance amid strong client acquisition.

Stonehorse Energy Limited outperformed production forecasts in Q4 2024 despite a revenue dip caused by weak natural gas prices, while advancing new project negotiations in Canada and the US.

Advanced Health Intelligence Ltd has locked in a USD$4 million convertible note facility with UAE-based KOR Investments LLC, aiming to raise up to AUD$10 million to fuel its MENA expansion and reduce debt.

Champion Iron reported solid Q3 FY2025 results despite a two-week shipment interruption, while progressing its DRPF upgrade and forging a key partnership for the Kami Project.

Champion Iron reports solid operational progress with 3.6 million wmt production and key partnerships, despite a sharp net income decline in Q3 FY2025.

Patronus Resources reports significant drilling progress across its Western Australia and Northern Territory projects, with strong assay results at Mertondale and a robust cash position supporting ongoing exploration.

Asset Vision Co Limited has reported a robust Q2 FY25, marked by significant revenue growth, improved cash flow, and effective cost management, positioning the company well for continued expansion.

Coventry Group reports a slight dip in H1 FY25 sales but manages a modest EBITDA increase, buoyed by a successful ERP upgrade and strategic growth initiatives.

Bioxyne Limited has raised its FY2025 revenue forecast to $25 million, driven by a remarkable 267% increase in first-half revenue and strong momentum from its subsidiary Breathe Life Sciences.